<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:05:47Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8392797" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8392797</identifier>
        <datestamp>2021-08-28</datestamp>
        <setSpec>tardis</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" xml:lang="en" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Ther Adv Respir Dis</journal-id>
              <journal-id journal-id-type="publisher-id">TAR</journal-id>
              <journal-id journal-id-type="hwp">sptar</journal-id>
              <journal-title-group>
                <journal-title>Therapeutic Advances in Respiratory Disease</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1753-4658</issn>
              <issn pub-type="epub">1753-4666</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage UK: London, England</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8392797</article-id>
              <article-id pub-id-type="pmcid">PMC8392797</article-id>
              <article-id pub-id-type="pmc-uid">8392797</article-id>
              <article-id pub-id-type="pmid">34428980</article-id>
              <article-id pub-id-type="pmid">34428980</article-id>
              <article-id pub-id-type="doi">10.1177/17534666211034329</article-id>
              <article-id pub-id-type="publisher-id">10.1177_17534666211034329</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Improvements in lung function with
budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler
<italic toggle="yes">versus</italic> dual therapies in patients with COPD: a sub-study of
the ETHOS trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7020-1401</contrib-id>
                  <name>
                    <surname>Rabe</surname>
                    <given-names>Klaus F.</given-names>
                  </name>
                  <xref rid="corresp1-17534666211034329" ref-type="corresp"/>
                  <aff id="aff1-17534666211034329">LungenClinic Grosshansdorf and
Christian-Albrechts University Kiel, Airway Research Center North, Member of
the German Center for Lung Research (DZL), Grosshansdorf 22927,
Germany</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Martinez</surname>
                    <given-names>Fernando J.</given-names>
                  </name>
                  <aff id="aff2-17534666211034329">Joan and Sanford I. Weill Department of
Medicine, Weill Cornell Medicine, New York, NY, USA</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Singh</surname>
                    <given-names>Dave</given-names>
                  </name>
                  <aff id="aff3-17534666211034329">Medicines Evaluation Unit, University of
Manchester, Manchester University NHS Foundation Trust, Manchester, UK</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Trivedi</surname>
                    <given-names>Roopa</given-names>
                  </name>
                  <aff id="aff4-17534666211034329">AstraZeneca, Durham, NC, USA</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jenkins</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <aff id="aff5-17534666211034329">AstraZeneca, Cambridge, UK</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Darken</surname>
                    <given-names>Patrick</given-names>
                  </name>
                  <aff id="aff6-17534666211034329">AstraZeneca, Gaithersburg, MD, USA</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Aurivillius</surname>
                    <given-names>Magnus</given-names>
                  </name>
                  <aff id="aff7-17534666211034329">AstraZeneca, Gothenburg, Sweden</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dorinsky</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <aff id="aff8-17534666211034329">AstraZeneca, Durham, NC, USA</aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="corresp1-17534666211034329">
                  <email>k.f.rabe@lungenclinic.de</email>
                </corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <season>Jan-Dec</season>
                <year>2021</year>
              </pub-date>
              <volume>15</volume>
              <elocation-id>17534666211034329</elocation-id>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>1</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>25</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s), 2021</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <related-object source-id="https://publons.com/publon/10.1177/17534666211034329" source-id-type="url" source-type="peer-review-report" id="d64e123"/>
              <abstract>
                <sec id="section1-17534666211034329">
                  <title>Background:</title>
                  <p>In the phase III, 52-week ETHOS study in patients with moderate to very
severe chronic obstructive pulmonary disease (COPD), triple therapy with
budesonide/glycopyrrolate/formoterol fumarate (BGF), at two inhaled
corticosteroid dose levels, resulted in significantly lower moderate/severe
exacerbation rates <italic toggle="yes">versus</italic> glycopyrrolate/formoterol
fumarate (GFF) and budesonide/formoterol fumarate (BFF). Here, we report
results from the ETHOS pulmonary function test (PFT) sub-study, which
assessed lung function in a subset of ETHOS patients.</p>
                </sec>
                <sec id="section2-17534666211034329">
                  <title>Methods:</title>
                  <p>ETHOS (NCT02465567) was a randomized, double-blind, multi-center,
parallel-group study in patients with moderate to very severe COPD who had
experienced ⩾1 moderate/severe exacerbation in the previous year. Patients
received BGF 320/18/9.6 µg, BGF 160/18/9.6 μg, GFF 18/9.6 µg, or BFF
320/9.6 µg twice daily <italic toggle="yes">via</italic> a single metered dose Aerosphere
inhaler for 52 weeks. A subset of patients participated in the 4-hour PFT
sub-study; primary endpoints were change from baseline in morning pre-dose
trough forced expiratory volume in one second (FEV<sub>1</sub>)
<italic toggle="yes">versus</italic> GFF and FEV<sub>1</sub> area under the curve
from 0 to 4 hours (AUC<sub>0–4</sub>) <italic toggle="yes">versus</italic> BFF at week
24.</p>
                </sec>
                <sec id="section3-17534666211034329">
                  <title>Results:</title>
                  <p>The PFT modified intent-to-treat population included 3088 patients (mean age
64.4 years; mean reversibility post-albuterol 16.7%; mean post-albuterol
FEV<sub>1</sub>% predicted 42.8). BGF 320/18/9.6 µg and 160/18/9.6 µg
significantly improved morning pre-dose trough FEV<sub>1</sub> at week 24
<italic toggle="yes">versus</italic> GFF (<italic toggle="yes">p</italic> ⩽ 0.0035 for both).
Improvements in trough FEV<sub>1</sub> were also observed at week 52 for BGF
320/18/9.6 µg and 160/18/9.6 µg <italic toggle="yes">versus</italic> GFF
(<italic toggle="yes">p</italic> ⩽ 0.0005 for both). For FEV<sub>1</sub>
AUC<sub>0–4</sub> at week 24, BGF 320/18/9.6 µg and 160/18/9.6 µg showed
significant improvements <italic toggle="yes">versus</italic> BFF
(<italic toggle="yes">p</italic> &lt; 0.0001 for both). Improvements were maintained at
week 52 (<italic toggle="yes">p</italic> &lt; 0.0001).</p>
                </sec>
                <sec id="section4-17534666211034329">
                  <title>Conclusions:</title>
                  <p>BGF 320/18/9.6 µg and 160/18/9.6 µg significantly improved trough
FEV<sub>1</sub>
<italic toggle="yes">versus</italic> GFF and FEV<sub>1</sub> AUC<sub>0–4</sub>
<italic toggle="yes">versus</italic> BFF at week 24. The lung function benefits with both
doses of BGF were maintained following 52 weeks of treatment.</p>
                  <p>
                    <italic toggle="yes">The reviews of this paper are available via the supplemental
material section.</italic>
                  </p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>BGF metered dose inhaler</kwd>
                <kwd>chronic obstructive pulmonary disease</kwd>
                <kwd>inhaled corticosteroid/long-acting muscarinic antagonist/long-acting
β<sub>2</sub>-agonist (ICS/LAMA/LABA)</kwd>
                <kwd>pulmonary function</kwd>
                <kwd>triple therapy</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="award1-17534666211034329">
                  <funding-source id="funding1-17534666211034329">
                    <institution-wrap>
                      <institution>AstraZeneca</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100004325</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January-December 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="section5-17534666211034329">
              <title>Introduction</title>
              <p>Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation
and is ranked as the third leading cause of mortality worldwide.<sup><xref rid="bibr1-17534666211034329" ref-type="bibr">1</xref><xref rid="bibr2-17534666211034329" ref-type="bibr"/>–<xref rid="bibr3-17534666211034329" ref-type="bibr">3</xref></sup> In 2017, COPD had a global
prevalence of approximately 300 million cases,<sup><xref rid="bibr4-17534666211034329" ref-type="bibr">4</xref></sup> was associated with approximately 3.2 million deaths,<sup><xref rid="bibr5-17534666211034329" ref-type="bibr">5</xref></sup> and was ranked as the seventh leading cause of disability worldwide.<sup><xref rid="bibr5-17534666211034329" ref-type="bibr">5</xref></sup></p>
              <p>The use of inhaled corticosteroid/long-acting muscarinic antagonist/long-acting
β<sub>2</sub>-agonist (ICS/LAMA/LABA) triple therapy is recommended for patients
with COPD who experience persistent exacerbations, defined as an acute worsening of
respiratory symptoms resulting in the need for additional therapy, or symptoms
despite the use of dual LAMA/LABA, or ICS/LABA inhaled therapies.<sup><xref rid="bibr3-17534666211034329" ref-type="bibr">3</xref></sup> In such patients, triple therapies have been shown to improve lung function
and symptoms and reduce the frequency of COPD exacerbations relative to dual
combination therapies.<sup><xref rid="bibr3-17534666211034329" ref-type="bibr">3</xref></sup></p>
              <p>In the ETHOS study (NCT02465567), the efficacy and safety of the ICS/LAMA/LABA triple
fixed-dose combination therapy budesonide/glycopyrrolate/formoterol fumarate (BGF),
at two ICS dose levels, delivered twice daily <italic toggle="yes">via</italic> a single metered
dose Aerosphere inhaler, was assessed over a 52-week treatment period in symptomatic
patients with moderate to very severe COPD, who had experienced at least one
moderate or severe exacerbation in the previous 12 months. Moderate exacerbations
were defined as those treated with corticosteroids with or without an antibiotic,
and severe exacerbations were defined as those resulting in hospitalization or death.<sup><xref rid="bibr6-17534666211034329" ref-type="bibr">6</xref></sup> Treatment with BGF showed a significant reduction in the rate of
moderate/severe COPD exacerbations, and improved symptoms and quality of life
compared with glycopyrrolate/formoterol fumarate (GFF) and budesonide/formoterol
fumarate (BFF).<sup><xref rid="bibr7-17534666211034329" ref-type="bibr">7</xref></sup> In addition, BGF 320/18/9.6 μg significantly reduced mortality
<italic toggle="yes">versus</italic> GFF [hazard ratio 0.51, 95% confidence interval (CI)
0.33–0.80; unadjusted <italic toggle="yes">p</italic>-value 0.0035].<sup><xref rid="bibr8-17534666211034329" ref-type="bibr">8</xref></sup></p>
              <p>A previous study of BGF, KRONOS, assessed symptomatic patients with moderate to very
severe COPD without a requirement for a history of exacerbations (NCT02497001);
primary endpoints were change from baseline in morning pre-dose trough forced
expiratory volume in one second (FEV<sub>1</sub>) <italic toggle="yes">versus</italic> GFF and
FEV<sub>1</sub> area under the curve from 0 to 4 hours post-dose
(AUC<sub>0–4</sub>) <italic toggle="yes">versus</italic> BFF at week 24. In the KRONOS study,
BGF 320/18/9.6 μg significantly improved FEV<sub>1</sub> AUC<sub>0–4</sub> at week
24 compared with BFF; however, the improvement in the change from baseline in
morning pre-dose trough FEV<sub>1</sub> at week 24 for BGF 320/18/9.6 μg compared
with GFF did not reach statistical significance.<sup><xref rid="bibr9-17534666211034329" ref-type="bibr">9</xref></sup></p>
              <p>Here, we report data from the ETHOS pulmonary function test (PFT) sub-study, which
assessed the effect of BGF relative to GFF and BFF on lung function, including the
effect on the rate of decline, in a subset of patients in the ETHOS study,
throughout the 52-week treatment period. In addition, we performed subgroup analyses
based on FEV<sub>1</sub> severity and blood eosinophil count at baseline.</p>
            </sec>
            <sec sec-type="methods" id="section6-17534666211034329">
              <title>Methods</title>
              <sec id="section7-17534666211034329">
                <title>Study design</title>
                <p>Details of the primary ETHOS study design have been published.<sup><xref rid="bibr10-17534666211034329" ref-type="bibr">10</xref>,<xref rid="bibr11-17534666211034329" ref-type="bibr">11</xref></sup> Briefly,
ETHOS was a 52-week, randomized, double-blind, parallel-group trial conducted
across 26 countries. Patients received twice daily dosing with BGF
320/18/9.6<bold> </bold>µg, BGF 160/18/9.6<bold> </bold>μg, GFF
18/9.6<bold> </bold>µg, or BFF 320/9.6<bold> </bold>µg. All treatments were
administered <italic toggle="yes">via</italic> oral inhalation from a single metered dose
Aerosphere inhaler; doses represent the sum of two actuations.</p>
                <p>Eligible patients for the ETHOS study were 40–80 years of age, with symptomatic
COPD (COPD assessment test score ⩾10 at screening despite receiving ⩾2 inhaled
maintenance therapies), had a post-bronchodilator FEV<sub>1</sub> 25–65% of
predicted normal, and had a smoking history of ⩾10 pack-years. If
post-bronchodilator FEV<sub>1</sub> was &lt;50% of predicted normal, patients
required a history of ⩾1 moderate or severe COPD exacerbation in the previous
year, and if post-bronchodilator FEV<sub>1</sub> was ⩾50% of predicted normal, a
history of ⩾2 moderate or ⩾1 severe COPD exacerbations was required. Patients
with a current diagnosis of asthma, respiratory disease other than COPD, or
other significant uncontrolled diseases (including cardiac disease and cancer)
were excluded.<sup><xref rid="bibr10-17534666211034329" ref-type="bibr">10</xref>,<xref rid="bibr11-17534666211034329" ref-type="bibr">11</xref></sup></p>
                <p>A subset of study sites was designated for participation in the PFT sub-study,
which was conducted concurrently with the full study. For inclusion in the PFT
sub-study, the average of the 60- and 30-minute pre-dose FEV<sub>1</sub>
assessments was required to be &lt;65% predicted normal value at visit 4. In
addition, patients were excluded from the PFT sub-study if they failed to meet
American Thoracic Society/European Respiratory Society spirometry criteria for
acceptability and repeatability.<sup><xref rid="bibr12-17534666211034329" ref-type="bibr">12</xref></sup> In order to ensure that baseline FEV<sub>1</sub> values were stable and
reflective of their true COPD severity during the screening period but prior to
randomization, patients who did not meet FEV<sub>1</sub> baseline stability
criteria were also excluded; this was defined as the average of the 60- and
30-minute pre-dose FEV<sub>1</sub> assessments at the randomization visit being
within ±20% or 200 mL of the mean pre-dose FEV<sub>1</sub> obtained at the two
previous visits.</p>
              </sec>
              <sec id="section8-17534666211034329">
                <title>Lung function endpoints and assessments</title>
                <p>Primary endpoints of the PFT sub-study included change from baseline in morning
pre-dose trough FEV<sub>1</sub> at week 24 and over 24 weeks for BGF
<italic toggle="yes">versus</italic> GFF, and FEV<sub>1</sub> AUC<sub>0–4</sub> post-dose
at week 24 and over 24 weeks for BGF <italic toggle="yes">versus</italic> BFF. Endpoints at
week 24 were part of the US Food and Drug Administration (FDA) registration
requirements and endpoints over 24 weeks were part of the European Medicines
Agency (EMA) registration requirements. Other lung function endpoints included
change from baseline in morning pre-dose trough FEV<sub>1</sub> over 52 weeks,
FEV<sub>1</sub> AUC<sub>0–4</sub> over 52 weeks, the onset of action
(defined as the first time point at which the mean change from baseline in
FEV<sub>1</sub> exceeded 100 mL), and the rate of decline in pre-dose
FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–4</sub> over 52 weeks.
Baseline for all FEV<sub>1</sub> analyses was calculated as the mean of 60- and
30-minute pre-dose FEV<sub>1</sub> values obtained at randomization.</p>
                <p>During the PFT sub-study, spirometry assessments were obtained at day 1 and weeks
4, 12, 24, 36, and 52. At these visits, spirometry assessments were conducted at
60 minutes and 30 minutes pre-dose and 5 (day 1 only), 15, and 30 minutes, and
1, 2, and 4 hours post-dose.</p>
                <p>The FEV<sub>1</sub> AUC<sub>0–4</sub> was calculated using the trapezoidal rule,
after first having subtracted the baseline FEV<sub>1</sub> value, and the AUC
was transformed into a weighted average by dividing by the time in hours from
dosing to the last measurement included (typically 4 hours).</p>
              </sec>
              <sec id="section9-17534666211034329">
                <title>Statistical analyses</title>
                <p>The PFT sub-study population was a subset of the patients in the modified
intent-to-treat (mITT) population of the ETHOS study. The overall mITT
population included all patients who were randomly assigned and treated and had
post-randomization data obtained before discontinuation of treatment. The change
from baseline in morning pre-dose trough FEV<sub>1</sub> and differences between
treatment groups in FEV<sub>1</sub> AUC<sub>0–4</sub> were analyzed using a
repeated measures linear mixed model. The model included baseline
FEV<sub>1</sub>, log baseline blood eosinophil count, and percentage
reversibility to bronchodilator as continuous covariates, and visit, treatment,
treatment by visit interaction, and ICS use at baseline as categorical
covariates. Other endpoints were analyzed using a similar repeated measures
linear mixed model such as morning pre-dose trough FEV<sub>1</sub>. The rates of
decline in morning pre-dose trough FEV<sub>1</sub> and FEV<sub>1</sub>
AUC<sub>0–4</sub> were analyzed with a linear mixed model with random
patient slopes of FEV<sub>1</sub>
<italic toggle="yes">versus</italic> time, and random patient intercepts. The rate of decline
(the negative of the slope) was estimated and compared between treatments. The
model included similar covariates to the analysis of trough FEV<sub>1</sub> but
with time in weeks as a continuous covariate in place of visit, smoking status
as an additional categorical covariate and interactions between time and
treatment, smoking status and baseline FEV<sub>1</sub>. Rate of decline analyses
used changes from the week 4 visit. In addition, patients were stratified into
subgroups based on post-bronchodilator FEV<sub>1</sub> predicted (&lt;50% and
⩾50%) and baseline blood eosinophil count (&lt;150 cells/mm<sup>3</sup>
<italic toggle="yes">versus</italic> ⩾150 cells/mm<sup>3</sup>) to evaluate the potential
impact of intrinsic or extrinsic factors on the results.</p>
                <p>The primary endpoints were part of a type I error control procedure used for
reporting the full ETHOS study. Other endpoints were not multiplicity controlled
and were reported in terms of unadjusted <italic toggle="yes">p</italic>-values.
Interpretation of results in subgroups relied on estimation and CIs.</p>
                <p>In order to examine further the potential impact of lung function severity and
eosinophil counts on lung function decline over one year, we performed an
exploratory analysis of lung function decline in a pooled cohort of
ICS-containing therapies (BGF 320/18/9.6 µg, BGF 160/18/9.6 μg, and BFF
320/9.6 µg) <italic toggle="yes">versus</italic> the non-ICS-containing therapy cohort (GFF
18/9.6 μg). As ICS may modulate lung function decline,<sup><xref rid="bibr13-17534666211034329" ref-type="bibr">13</xref>,<xref rid="bibr14-17534666211034329" ref-type="bibr">14</xref></sup> the ICS-containing
therapies were combined into a single group to reduce variability and increase
overall sample size of the lung function severity and eosinophil subgroups.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section10-17534666211034329">
              <title>Results</title>
              <sec id="section11-17534666211034329">
                <title>Study population</title>
                <p>A total of 3088 patients were included in the 4-hour PFT sub-study (36.3% of the
total ETHOS mITT population; mean age 64.4 years; mean reversibility
post-albuterol 16.7%; mean post-albuterol FEV<sub>1</sub>% predicted, 42.8%;
<xref rid="table1-17534666211034329" ref-type="table">Table 1</xref>).
Patient demographics were generally similar to those of the overall ETHOS mITT population.<sup><xref rid="bibr10-17534666211034329" ref-type="bibr">10</xref></sup></p>
                <table-wrap position="float" id="table1-17534666211034329">
                  <label>Table 1.</label>
                  <caption>
                    <p>Demographics and baseline characteristics (PFT sub-study mITT
population).</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_17534666211034329-table1" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">BGF 320/18/9.6 µg <italic toggle="yes">n</italic> = 747</th>
                          <th align="left" rowspan="1" colspan="1">BGF 160/18/9.6 µg <italic toggle="yes">n</italic> = 807</th>
                          <th align="left" rowspan="1" colspan="1">GFF 18/9.6 µg <italic toggle="yes">n</italic> = 779</th>
                          <th align="left" rowspan="1" colspan="1">BFF 320/9.6 µg <italic toggle="yes">n</italic> = 755</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td rowspan="1" colspan="1">Age, years, mean (SD)</td>
                          <td rowspan="1" colspan="1">64.3 (7.5)</td>
                          <td rowspan="1" colspan="1">64.4 (7.6)</td>
                          <td rowspan="1" colspan="1">64.8 (7.6)</td>
                          <td rowspan="1" colspan="1">64.3 (7.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">397 (53.1)</td>
                          <td rowspan="1" colspan="1">441 (54.6)</td>
                          <td rowspan="1" colspan="1">386 (49.6)</td>
                          <td rowspan="1" colspan="1">407 (53.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">CAT score, mean (SD)<sup><xref rid="table-fn1-17534666211034329" ref-type="table-fn">a</xref></sup></td>
                          <td rowspan="1" colspan="1">20.2 (6.5)</td>
                          <td rowspan="1" colspan="1">20.5 (6.6)</td>
                          <td rowspan="1" colspan="1">20.3 (6.8)</td>
                          <td rowspan="1" colspan="1">20.4 (6.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>, mean (SD)<sup><xref rid="table-fn2-17534666211034329" ref-type="table-fn">b</xref></sup></td>
                          <td rowspan="1" colspan="1">28.4 (6.6)</td>
                          <td rowspan="1" colspan="1">28.3 (6.9)</td>
                          <td rowspan="1" colspan="1">28.6 (6.6)</td>
                          <td rowspan="1" colspan="1">27.9 (6.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Current smoker, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">331 (44.3)</td>
                          <td rowspan="1" colspan="1">351 (43.5)</td>
                          <td rowspan="1" colspan="1">336 (43.1)</td>
                          <td rowspan="1" colspan="1">339 (44.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">No. pack-years smoked,<sup><xref rid="table-fn3-17534666211034329" ref-type="table-fn">c</xref></sup> median (range)</td>
                          <td rowspan="1" colspan="1">44.0 (10.0–150.0)</td>
                          <td rowspan="1" colspan="1">44.6 (10.0–187.5)</td>
                          <td rowspan="1" colspan="1">43.0 (10.0–168.0)</td>
                          <td rowspan="1" colspan="1">44.0 (10.0–250.0)</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Baseline eosinophil count, <italic toggle="yes">n</italic>
(%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &lt;100 cells/mm<sup>3</sup></td>
                          <td rowspan="1" colspan="1">106 (14.2)</td>
                          <td rowspan="1" colspan="1">120 (14.9)</td>
                          <td rowspan="1" colspan="1">95 (12.2)</td>
                          <td rowspan="1" colspan="1">100 (13.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ⩾100 cells/mm<sup>3</sup></td>
                          <td rowspan="1" colspan="1">641 (85.8)</td>
                          <td rowspan="1" colspan="1">687 (85.1)</td>
                          <td rowspan="1" colspan="1">684 (87.8)</td>
                          <td rowspan="1" colspan="1">655 (86.8)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &lt;150 cells/mm<sup>3</sup></td>
                          <td rowspan="1" colspan="1">255 (34.1)</td>
                          <td rowspan="1" colspan="1">303 (37.5)</td>
                          <td rowspan="1" colspan="1">266 (34.1)</td>
                          <td rowspan="1" colspan="1">247 (32.7)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ⩾150 cells/mm<sup>3</sup></td>
                          <td rowspan="1" colspan="1">492 (65.9)</td>
                          <td rowspan="1" colspan="1">504 (62.5)</td>
                          <td rowspan="1" colspan="1">513 (65.9)</td>
                          <td rowspan="1" colspan="1">508 (67.3)</td>
                        </tr>
                        <tr>
                          <td colspan="5" rowspan="1">Exacerbation history, <italic toggle="yes">n</italic>
(%)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> 1</td>
                          <td rowspan="1" colspan="1">349 (46.7)</td>
                          <td rowspan="1" colspan="1">371 (46.0)</td>
                          <td rowspan="1" colspan="1">352 (45.2)</td>
                          <td rowspan="1" colspan="1">343 (45.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ⩾2</td>
                          <td rowspan="1" colspan="1">398 (53.3)</td>
                          <td rowspan="1" colspan="1">436 (54.0)</td>
                          <td rowspan="1" colspan="1">427 (54.8)</td>
                          <td rowspan="1" colspan="1">412 (54.6)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Post-albuterol FEV<sub>1</sub>% of predicted normal, mean
(SD)</td>
                          <td rowspan="1" colspan="1">43.1 (10.4)</td>
                          <td rowspan="1" colspan="1">42.5 (10.4)</td>
                          <td rowspan="1" colspan="1">43.0 (10.3)</td>
                          <td rowspan="1" colspan="1">42.7 (10.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Reversibility post-albuterol FEV<sub>1</sub>,%, mean (SD)<sup><xref rid="table-fn4-17534666211034329" ref-type="table-fn">d</xref></sup></td>
                          <td rowspan="1" colspan="1">17.4 (16.6)</td>
                          <td rowspan="1" colspan="1">16.3 (16.3)</td>
                          <td rowspan="1" colspan="1">17.3 (15.9)</td>
                          <td rowspan="1" colspan="1">15.8 (15.4)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Reversible, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">264 (35.3)</td>
                          <td rowspan="1" colspan="1">257 (31.8)</td>
                          <td rowspan="1" colspan="1">280 (35.9)</td>
                          <td rowspan="1" colspan="1">251 (33.2)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">Use of ICS at screening, <italic toggle="yes">n</italic> (%)</td>
                          <td rowspan="1" colspan="1">562 (75.2)</td>
                          <td rowspan="1" colspan="1">628 (77.8)</td>
                          <td rowspan="1" colspan="1">598 (76.8)</td>
                          <td rowspan="1" colspan="1">573 (75.9)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn1-17534666211034329">
                      <label>a</label>
                      <p>BGF 320/18/9.6 µg, <italic toggle="yes">n =</italic> 745; BGF 160/18/9.6 µg,
<italic toggle="yes">n =</italic> 806.</p>
                    </fn>
                    <fn id="table-fn2-17534666211034329">
                      <label>b</label>
                      <p>BGF 160/18/9.6 µg, <italic toggle="yes">n =</italic> 806.</p>
                    </fn>
                    <fn id="table-fn3-17534666211034329">
                      <label>c</label>
                      <p>Number of pack-years smoked = (number of cigarettes per
day/20) × number of years smoked.</p>
                    </fn>
                    <fn id="table-fn4-17534666211034329">
                      <label>d</label>
                      <p>BGF 320/18/9.6 µg, <italic toggle="yes">n =</italic> 745; BGF 160/18/9.6 µg,
<italic toggle="yes">n =</italic> 806; GFF 18/9.6 µg,
<italic toggle="yes">n =</italic> 778; BFF 320/9.6 µg,
<italic toggle="yes">n =</italic> 753.</p>
                    </fn>
                    <fn id="table-fn5-17534666211034329">
                      <p>BFF, budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; CAT, COPD Assessment
Test; COPD, chronic obstructive pulmonary disease; FEV<sub>1</sub>,
forced expiratory volume in 1 second; GFF, glycopyrrolate/formoterol
fumarate; ICS, inhaled corticosteroid; mITT, modified
intent-to-treat; PFT, pulmonary function test; SD, standard
deviation.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="section12-17534666211034329">
                <title>Morning pre-dose trough FEV<sub>1</sub></title>
                <p>BGF 320/18/9.6 μg treatment resulted in significant improvements in least squares
(LS) mean change from baseline morning pre-dose trough FEV<sub>1</sub> at week
24 compared with GFF (35 mL; <italic toggle="yes">p-</italic>value 0.0025; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>) and BFF
(76 mL; unadjusted <italic toggle="yes">p-</italic>value &lt; 0.0001; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>). Treatment with BGF
160/18/9.6 μg also significantly improved LS mean change from baseline in
morning pre-dose trough FEV<sub>1</sub> at week 24 compared with GFF (33 mL;
<italic toggle="yes">p-</italic>value 0.0035; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>) and BFF (74 mL; unadjusted
<italic toggle="yes">p-</italic>value &lt; 0.0001; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>).</p>
                <table-wrap position="float" id="table2-17534666211034329">
                  <label>Table 2.</label>
                  <caption>
                    <p>Change from baseline<sup><xref rid="table-fn6-17534666211034329" ref-type="table-fn">a</xref></sup> in morning pre-dose trough FEV<sub>1</sub> and FEV<sub>1</sub>
AUC<sub>0–4</sub> (efficacy estimand; PFT sub-study mITT population<sup><xref rid="table-fn7-17534666211034329" ref-type="table-fn">b</xref></sup>).</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_17534666211034329-table2" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="1" colspan="1"/>
                          <th rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> GFF
18/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 160/18/9.6 μg <italic toggle="yes">versus</italic> GFF
18/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> BFF
320/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 160/18/9.6 μg <italic toggle="yes">versus</italic> BFF
320/9.6 μg</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="6" rowspan="1">Change from baseline in morning pre-dose trough
FEV<sub>1</sub>, mL<sup><xref rid="table-fn8-17534666211034329" ref-type="table-fn">c</xref></sup></td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> At week 24</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">
                            <bold>35 (12, 57)</bold>
                          </td>
                          <td rowspan="1" colspan="1">
                            <bold>33 (11, 55)</bold>
                          </td>
                          <td rowspan="1" colspan="1">76 (54, 99)</td>
                          <td rowspan="1" colspan="1">74 (52, 96)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">
                            <bold>0.0025</bold>
                          </td>
                          <td rowspan="1" colspan="1">
                            <bold>0.0035</bold>
                          </td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Over 24 weeks</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">
                            <bold>43 (25, 60)</bold>
                          </td>
                          <td rowspan="1" colspan="1">
                            <bold>30 (12, 47)</bold>
                          </td>
                          <td rowspan="1" colspan="1">76 (58, 94)</td>
                          <td rowspan="1" colspan="1">63 (46, 81)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">
                            <bold>&lt;0.0001</bold>
                          </td>
                          <td rowspan="1" colspan="1">
                            <bold>0.0009</bold>
                          </td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> At week 52</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">55 (30, 79)</td>
                          <td rowspan="1" colspan="1">43 (18, 67)</td>
                          <td rowspan="1" colspan="1">65 (40, 89)</td>
                          <td rowspan="1" colspan="1">53 (29, 77)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">0.0005</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Over 52 weeks</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">46 (27, 64)</td>
                          <td rowspan="1" colspan="1">36 (18, 54)</td>
                          <td rowspan="1" colspan="1">72 (54, 90)</td>
                          <td rowspan="1" colspan="1">62 (45, 80)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td colspan="6" rowspan="1">FEV<sub>1</sub> AUC<sub>0–4</sub>, mL<sup><xref rid="table-fn8-17534666211034329" ref-type="table-fn">c</xref></sup></td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> At week 24</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">53 (29, 77)</td>
                          <td rowspan="1" colspan="1">43 (19, 66)</td>
                          <td rowspan="1" colspan="1">
                            <bold>119 (95, 143)</bold>
                          </td>
                          <td rowspan="1" colspan="1">
                            <bold>109 (85, 132)</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">0.0004</td>
                          <td rowspan="1" colspan="1">
                            <bold>&lt;0.0001</bold>
                          </td>
                          <td rowspan="1" colspan="1">&lt;<bold>0.0001</bold></td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Over 24 weeks</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">49 (31, 66)</td>
                          <td rowspan="1" colspan="1">34 (17, 51)</td>
                          <td rowspan="1" colspan="1">
                            <bold>99 (82, 117)</bold>
                          </td>
                          <td rowspan="1" colspan="1">
                            <bold>85 (67, 102)</bold>
                          </td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;<bold>0.0001</bold></td>
                          <td rowspan="1" colspan="1">&lt;<bold>0.0001</bold></td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> At week 52</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">66 (40, 92)</td>
                          <td rowspan="1" colspan="1">55 (30, 80)</td>
                          <td rowspan="1" colspan="1">108 (82, 133)</td>
                          <td rowspan="1" colspan="1">97 (71, 122)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Over 52 weeks</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">53 (35, 71)</td>
                          <td rowspan="1" colspan="1">41 (23, 59)</td>
                          <td rowspan="1" colspan="1">102 (84, 120)</td>
                          <td rowspan="1" colspan="1">90 (72, 108)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn6-17534666211034329">
                      <label>a</label>
                      <p>Baseline was defined as the mean of the 30- and 60-minute values
prior to dosing on day 1, if available; otherwise, the mean of the
30- and 60-minute pre-bronchodilator assessments at visit 3 were
used, if available; otherwise, the mean of the 30- and 60-minute
pre-bronchodilator assessments at visit 2 were used.</p>
                    </fn>
                    <fn id="table-fn7-17534666211034329">
                      <label>b</label>
                      <p>mITT population: BGF 320/18/9.6 μg, <italic toggle="yes">n =</italic> 747; BGF
160/18/9.6 μg, <italic toggle="yes">n =</italic> 807; GFF 18/9.6 μg,
<italic toggle="yes">n =</italic> 779; BFF 320/9.6 μg,
<italic toggle="yes">n =</italic> 755.</p>
                    </fn>
                    <fn id="table-fn8-17534666211034329">
                      <label>c</label>
                      <p>The pre-specified treatment comparisons of interest were both doses
of BGF <italic toggle="yes">versus</italic> GFF (for trough FEV<sub>1</sub>), and
both doses of BGF <italic toggle="yes">versus</italic> BFF (for FEV<sub>1</sub>
AUC<sub>0–4</sub>). Results in bold were type I
error-controlled; all other comparisons were not adjusted for
multiplicity.</p>
                    </fn>
                    <fn id="table-fn9-17534666211034329">
                      <p>AUC<sub>0–4</sub>, area under the curve from 0 to 4 hours post-dose;
BFF, budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; CI, confidence
interval; FEV<sub>1</sub>, forced expiratory volume in 1 second;
GFF, glycopyrrolate/formoterol fumarate; LSM, least squares mean;
mITT, modified intent-to-treat; PFT, pulmonary function test.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Significant improvements in morning pre-dose trough FEV<sub>1</sub> were
maintained at week 52 for BGF 320/18/9.6 µg and BGF 160/18/9.6 µg
<italic toggle="yes">versus</italic> both GFF and BFF (unadjusted
<italic toggle="yes">p-</italic>value ⩽ 0.0005; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>). Improvements in morning
pre-dose trough FEV<sub>1</sub> with both doses of BGF <italic toggle="yes">versus</italic>
GFF and BFF were sustained throughout the 52-week treatment period (<xref rid="fig1-17534666211034329" ref-type="fig">Figure 1</xref>). While there
was no appreciable difference between BGF doses at week 24, there was a small
numerical difference in favor of BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> BGF
160/18/9.6 μg over 24 weeks (<xref rid="fig1-17534666211034329" ref-type="fig">Figure 1</xref>; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>).</p>
                <fig position="float" id="fig1-17534666211034329">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Change from baseline in morning pre-dose trough FEV<sub>1</sub> over
study duration (efficacy estimand; PFT mITT sub-study population).</p>
                    <p>Data are adjusted mean ± standard error.</p>
                    <p>BFF, budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; FEV<sub>1</sub>, forced
expiratory volume in 1 second; GFF, glycopyrrolate/formoterol fumarate;
mITT, modified intent-to-treat; PFT, pulmonary function test.</p>
                  </caption>
                  <graphic xlink:href="10.1177_17534666211034329-fig1" position="float"/>
                </fig>
              </sec>
              <sec id="section13-17534666211034329">
                <title>FEV<sub>1</sub> AUC<sub>0–4</sub></title>
                <p>BGF 320/18/9.6 μg treatment resulted in significant improvements in LS mean
FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24 compared with BFF (119 mL;
<italic toggle="yes">p-</italic>value &lt; 0.0001; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>) and GFF (53 mL; unadjusted
<italic toggle="yes">p-</italic>value &lt; 0.0001; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>). Treatment with BGF
160/18/9.6 μg also significantly improved LS mean FEV<sub>1</sub>
AUC<sub>0–4</sub> at week 24 compared with BFF (109 mL;
<italic toggle="yes">p-</italic>value &lt; 0.0001) and GFF (43 mL; unadjusted
<italic toggle="yes">p-</italic>value 0.0004; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>). There were small numerical
differences in favor of BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> BGF
160/18/9.6 μg both at week 24 and over 24 weeks (<xref rid="fig2-17534666211034329" ref-type="fig">Figure 2</xref>; <xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>).</p>
                <fig position="float" id="fig2-17534666211034329">
                  <label>Figure 2.</label>
                  <caption>
                    <p>FEV<sub>1</sub> AUC<sub>0–4</sub> over study duration (efficacy estimand;
PFT mITT sub-study population).</p>
                    <p>Data are adjusted mean ± standard error.</p>
                    <p>AUC<sub>0–4</sub>, area under the curve from 0 to 4 hours post-dose; BFF,
budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; FEV<sub>1</sub>, forced
expiratory volume in 1 second; GFF, glycopyrrolate/formoterol fumarate;
mITT, modified intent-to-treat; PFT, pulmonary function test.</p>
                  </caption>
                  <graphic xlink:href="10.1177_17534666211034329-fig2" position="float"/>
                </fig>
                <p>Significant improvements in FEV<sub>1</sub> AUC<sub>0–4</sub> were maintained at
week 52 for BGF 320/18/9.6 μg and BGF 160/18/9.6 μg <italic toggle="yes">versus</italic> BFF
and GFF (unadjusted <italic toggle="yes">p-</italic>value &lt;0.0001 for all comparisons;
<xref rid="table2-17534666211034329" ref-type="table">Table 2</xref>).
Improvements in FEV<sub>1</sub> AUC<sub>0–4</sub> with both doses of BGF
<italic toggle="yes">versus</italic> BFF and GFF were sustained throughout the 52-week
treatment period (<xref rid="fig2-17534666211034329" ref-type="fig">Figure
2</xref>).</p>
              </sec>
              <sec id="section14-17534666211034329">
                <title>Analyses by FEV<sub>1</sub>% predicted at baseline (&lt;50% versus
⩾50%)</title>
                <p>The effects of BGF <italic toggle="yes">versus</italic> GFF and BFF on morning pre-dose trough
FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24 in patients
with post-bronchodilator FEV<sub>1</sub> &lt; 50% and ⩾50% predicted were
directionally consistent with the overall findings but with slightly larger
estimated benefits in the subgroup with post-bronchodilator
FEV<sub>1</sub> ⩾ 50% (<xref rid="table3-17534666211034329" ref-type="table">Table 3</xref>).</p>
                <table-wrap position="float" id="table3-17534666211034329">
                  <label>Table 3.</label>
                  <caption>
                    <p>Change from baseline in morning pre-dose trough FEV<sub>1</sub> and
FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24 by post-bronchodilator
FEV<sub>1</sub>% predicted (efficacy estimand; PFT sub-study mITT
population).</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_17534666211034329-table3" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" colspan="2" rowspan="1">% Predicted post-bronchodilator
FEV<sub>1</sub></th>
                          <th align="left" rowspan="1" colspan="1">BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> GFF
18/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 160/18/9.6 μg <italic toggle="yes">versus</italic> GFF
18/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> BFF
320/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 160/18/9.6 μg <italic toggle="yes">versus</italic> BFF
320/9.6 μg</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="6" rowspan="1">Morning pre-dose trough FEV<sub>1</sub>, mL</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &lt;50% <italic toggle="yes">n</italic> = 2250</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">31 (7, 55)</td>
                          <td rowspan="1" colspan="1">29 (5, 53)</td>
                          <td rowspan="1" colspan="1">71 (47, 95)</td>
                          <td rowspan="1" colspan="1">69 (45, 92)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">0.0118</td>
                          <td rowspan="1" colspan="1">0.0180</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ⩾50% <italic toggle="yes">n</italic> = 838</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">47 (−4, 97)</td>
                          <td rowspan="1" colspan="1">47 (−2, 95)</td>
                          <td rowspan="1" colspan="1">90 (39, 140)</td>
                          <td rowspan="1" colspan="1">89 (40, 138)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">0.0705</td>
                          <td rowspan="1" colspan="1">0.0624</td>
                          <td rowspan="1" colspan="1">0.0006</td>
                          <td rowspan="1" colspan="1">0.0004</td>
                        </tr>
                        <tr>
                          <td colspan="6" rowspan="1">FEV<sub>1</sub> AUC<sub>0–4</sub>, mL</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> &lt;50% <italic toggle="yes">n</italic> = 2250</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">48 (22, 75)</td>
                          <td rowspan="1" colspan="1">39 (13, 65)</td>
                          <td rowspan="1" colspan="1">112 (86, 138)</td>
                          <td rowspan="1" colspan="1">103 (77, 129)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">0.0003</td>
                          <td rowspan="1" colspan="1">0.0036</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> ⩾50% <italic toggle="yes">n</italic> = 838</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">67 (16, 118)</td>
                          <td rowspan="1" colspan="1">57 (8, 107)</td>
                          <td rowspan="1" colspan="1">135 (83, 186)</td>
                          <td rowspan="1" colspan="1">125 (75, 175)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">0.0108</td>
                          <td rowspan="1" colspan="1">0.0241</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn10-17534666211034329">
                      <p>AUC<sub>0–4</sub>, area under the curve from 0 to 4 hours post-dose;
BFF, budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; CI, confidence
interval; FEV<sub>1</sub>, forced expiratory volume in 1 second;
GFF, glycopyrrolate/formoterol fumarate; LSM, least squares mean;
mITT, modified intent-to-treat; PFT, pulmonary function test.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="section15-17534666211034329">
                <title>Analyses by baseline blood eosinophil count (&lt;150 cells/mm<sup>3</sup>
versus ⩾150 cells/mm<sup>3</sup>)</title>
                <p>Similarly, the effects of BGF <italic toggle="yes">versus</italic> GFF and BFF on morning
pre-dose trough FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24
in patients with blood eosinophil count &lt;150 cells/mm<sup>3</sup> and
⩾150 cells/mm<sup>3</sup> were directionally consistent with the overall
findings but with slightly larger estimated benefits in the subgroup with blood
eosinophil count ⩾150 cells/mm<sup>3</sup> (<xref rid="table4-17534666211034329" ref-type="table">Table 4</xref>).</p>
                <table-wrap position="float" id="table4-17534666211034329">
                  <label>Table 4.</label>
                  <caption>
                    <p>Change from baseline in morning pre-dose trough FEV<sub>1</sub> and
FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24 by baseline blood
eosinophil count (efficacy estimand; PFT sub-study mITT population).</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_17534666211034329-table4" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" colspan="2" rowspan="1">Baseline eosinophil count</th>
                          <th align="left" rowspan="1" colspan="1">BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> GFF
18/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 160/18/9.6 μg <italic toggle="yes">versus</italic> GFF
18/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 320/18/9.6 μg <italic toggle="yes">versus</italic> BFF
320/9.6 μg</th>
                          <th align="left" rowspan="1" colspan="1">BGF 160/18/9.6 μg <italic toggle="yes">versus</italic> BFF
320/9.6 μg</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="6" rowspan="1">Morning pre-dose trough FEV<sub>1</sub>, mL</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">&lt;150 cells/mm<sup>3</sup>
<italic toggle="yes">n</italic> = 1071</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">12 (−24, 47)</td>
                          <td rowspan="1" colspan="1">−5 (−39, 29)</td>
                          <td rowspan="1" colspan="1">71 (34, 107)</td>
                          <td rowspan="1" colspan="1">54 (20, 89)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">0.5266</td>
                          <td rowspan="1" colspan="1">0.7828</td>
                          <td rowspan="1" colspan="1">0.0001</td>
                          <td rowspan="1" colspan="1">0.0022</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">⩾150 cells/mm<sup>3</sup>
<italic toggle="yes">n</italic> = 2017</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">45 (17, 74)</td>
                          <td rowspan="1" colspan="1">55 (26, 83)</td>
                          <td rowspan="1" colspan="1">77 (49, 105)</td>
                          <td rowspan="1" colspan="1">86 (58, 114)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">0.0019</td>
                          <td rowspan="1" colspan="1">0.0002</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td colspan="6" rowspan="1">FEV<sub>1</sub> AUC<sub>0–4</sub>, mL</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">&lt;150 cells/mm<sup>3</sup>
<italic toggle="yes">n</italic> = 1071</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">31 (−7, 68)</td>
                          <td rowspan="1" colspan="1">2 (−34, 37)</td>
                          <td rowspan="1" colspan="1">117 (79, 155)</td>
                          <td rowspan="1" colspan="1">88 (52, 124)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">0.1063</td>
                          <td rowspan="1" colspan="1">0.9317</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1">⩾150 cells/mm<sup>3</sup>
<italic toggle="yes">n</italic> = 2017</td>
                          <td rowspan="1" colspan="1">LSM (95% CI)</td>
                          <td rowspan="1" colspan="1">64 (33, 94)</td>
                          <td rowspan="1" colspan="1">68 (37, 98)</td>
                          <td rowspan="1" colspan="1">120 (89, 150)</td>
                          <td rowspan="1" colspan="1">123 (93, 153)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"><italic toggle="yes">p-</italic>value</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                          <td rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn11-17534666211034329">
                      <p>AUC<sub>0–4</sub>, area under the curve from 0 to 4 hours post-dose;
BFF, budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; CI, confidence
interval; FEV<sub>1</sub>, forced expiratory volume in 1 second;
GFF, glycopyrrolate/formoterol fumarate; LSM, least squares mean;
mITT, modified intent-to-treat; PFT, pulmonary function test.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>The change from baseline in morning pre-dose trough FEV<sub>1</sub> and
FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24 for both doses of BGF
<italic toggle="yes">versus</italic> GFF and BFF in patients with blood eosinophil counts
&lt;100 cells/mm<sup>3</sup>, 100–&lt;300 cells/mm<sup>3</sup>, and
⩾300 cells/mm<sup>3</sup> is shown in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666211034329" ext-link-type="uri">Supplemental Table 1</ext-link>. Larger changes from baseline in morning
pre-dose trough FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24
were seen for both doses of BGF <italic toggle="yes">versus</italic> GFF from blood
eosinophil counts ⩾100 cells/mm<sup>3</sup>, which increased as baseline blood
eosinophil count increased. Benefits were seen in morning pre-dose trough
FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–4</sub> at week 24 for both
doses of BGF <italic toggle="yes">versus</italic> BFF, although these did not vary across
eosinophil levels to the extent observed for BGF <italic toggle="yes">versus</italic>
GFF.</p>
              </sec>
              <sec id="section16-17534666211034329">
                <title>Onset of action</title>
                <p>Improvements in FEV<sub>1</sub> were achieved rapidly with post-dose changes from
baseline in FEV<sub>1</sub> being &gt;100 mL for all four treatment groups at
the 5-minute post-dose measurement (<xref rid="fig3-17534666211034329" ref-type="fig">Figure 3</xref>).</p>
                <fig position="float" id="fig3-17534666211034329">
                  <label>Figure 3.</label>
                  <caption>
                    <p>Change from baseline in FEV<sub>1</sub> over 4-hour post-dose interval at
day 1 (efficacy estimand; PFT mITT sub-study population).</p>
                    <p>Data are adjusted mean ± standard error.</p>
                    <p>BFF, budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; FEV<sub>1</sub>, forced
expiratory volume in 1 second; GFF, glycopyrrolate/formoterol fumarate;
mITT, modified intent-to-treat; PFT, pulmonary function test.</p>
                  </caption>
                  <graphic xlink:href="10.1177_17534666211034329-fig3" position="float"/>
                </fig>
              </sec>
              <sec id="section17-17534666211034329">
                <title>Analyses of ICS-containing therapies versus GFF on lung function
decline</title>
                <p>A trend for a lower rate of decline in morning pre-dose trough FEV<sub>1</sub>
over 52 weeks was observed in the BGF treatment groups relative to GFF
(<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666211034329" ext-link-type="uri">Supplemental Table 2</ext-link>). However, no consistent effects were
observed for a lower rate of decline in FEV<sub>1</sub> AUC<sub>0–4</sub> for
BGF relative to BFF (<ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666211034329" ext-link-type="uri">Supplemental Table 2</ext-link>).</p>
                <p>Patients treated with ICS-containing therapies were pooled to assess whether
benefits <italic toggle="yes">versus</italic> the non-ICS-containing therapy, GFF, were
driven by acute ICS withdrawal in patients who received ICS prior to
randomization and to increase the sample size of the subgroup. Pooling patients
treated with ICS-containing therapies showed lower annual rates of decline in
pre-dose trough FEV<sub>1</sub>
<italic toggle="yes">versus</italic> GFF [treatment difference −16.4 mL (95% CI −36.4 mL,
3.6 mL); <xref rid="table5-17534666211034329" ref-type="table">Table 5</xref>].
A smaller reduction in the annual rate of decline was also seen for
FEV<sub>1</sub> AUC<sub>0−4</sub> in patients treated with ICS-containing
therapies <italic toggle="yes">versus</italic> GFF [treatment difference −7.5 mL (95% CI
−26.5 mL, 11.6 mL); <xref rid="table5-17534666211034329" ref-type="table">Table
5</xref>]. Patients with moderate airflow obstruction (FEV<sub>1</sub> ⩾50%
predicted at baseline) and blood eosinophil counts ⩾100 cells/mm<sup>3</sup> had
a greater reduction in the adjusted annual rates of decline in morning pre-dose
trough FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–4</sub> when treated with
ICS-containing therapies <italic toggle="yes">versus</italic> GFF (<xref rid="fig4-17534666211034329" ref-type="fig">Figure 4</xref>).</p>
                <table-wrap position="float" id="table5-17534666211034329">
                  <label>Table 5.</label>
                  <caption>
                    <p>Adjusted rate of decline in morning pre-dose trough FEV<sub>1</sub> and
FEV<sub>1</sub> AUC<sub>0–4</sub> over 52 weeks by ICS-containing
therapy (efficacy estimand; PFT sub-study mITT population).</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="10.1177_17534666211034329-table5" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" span="1"/>
                        <col align="char" char="." span="1"/>
                        <col align="char" char="." span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th rowspan="1" colspan="1"/>
                          <th align="left" rowspan="1" colspan="1">ICS-containing therapy
<italic toggle="yes">N</italic> = 2309</th>
                          <th align="left" rowspan="1" colspan="1">GFF 18/9.6 μg <italic toggle="yes">N</italic> = 779</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="3" rowspan="1">Morning pre-dose FEV<sub>1</sub>, mL/year<sup><xref rid="table-fn12-17534666211034329" ref-type="table-fn">a</xref></sup></td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Adjusted rate of decline (SE)</td>
                          <td rowspan="1" colspan="1">37.7 (5.0)</td>
                          <td rowspan="1" colspan="1">54.0 (8.9)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Treatment difference (95% CI)</td>
                          <td rowspan="1" colspan="1">–</td>
                          <td rowspan="1" colspan="1">−16.4 (−36.4, 3.6)</td>
                        </tr>
                        <tr>
                          <td colspan="3" rowspan="1">FEV<sub>1</sub> AUC<sub>0–4</sub>, mL/year<sup><xref rid="table-fn13-17534666211034329" ref-type="table-fn">b</xref></sup></td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Adjusted rate of decline (SE)</td>
                          <td rowspan="1" colspan="1">56.1 (4.7)</td>
                          <td rowspan="1" colspan="1">63.6 (8.5)</td>
                        </tr>
                        <tr>
                          <td rowspan="1" colspan="1"> Treatment difference (95% CI)</td>
                          <td rowspan="1" colspan="1">–</td>
                          <td rowspan="1" colspan="1">−7.5 (−26.5, 11.6)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="table-fn12-17534666211034329">
                      <label>a</label>
                      <p>Rate of the decline of pre-dose trough FEV<sub>1</sub> is –1
multiplied by the average of the individual slope of pre-dose trough
FEV<sub>1</sub> over 52 weeks across patients for the
treatment.</p>
                    </fn>
                    <fn id="table-fn13-17534666211034329">
                      <label>b</label>
                      <p>Rate of the decline of FEV<sub>1</sub> AUC<sub>0–4</sub> is –1
multiplied by the average of the individual slope of FEV<sub>1</sub>
AUC<sub>0–4</sub> over 52 weeks across patients for the
treatment.</p>
                    </fn>
                    <fn id="table-fn14-17534666211034329">
                      <p>AUC<sub>0–4</sub>, area under the curve from 0 to 4 hours post-dose;
BFF, budesonide/formoterol fumarate; BGF,
budesonide/glycopyrrolate/formoterol fumarate; CI, confidence
interval; FEV<sub>1</sub>, forced expiratory volume in 1 second;
GFF, glycopyrrolate/formoterol fumarate; ICS, inhaled
corticosteroid; mITT, modified intent-to-treat; PFT, pulmonary
function test; SE, standard error.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" id="fig4-17534666211034329">
                  <label>Figure 4.</label>
                  <caption>
                    <p>Adjusted rate of decline in pre-dose trough FEV<sub>1</sub> (a) and
FEV<sub>1</sub> AUC<sub>0–4</sub> (b) over 52 weeks.</p>
                    <p>Size of data point relative to size of patient cohort; <italic toggle="yes">n</italic>
are for ICS-containing therapies and GFF 18/9.6 ug, respectively.</p>
                    <p>AUC<sub>0–4</sub>, area under the curve 0 to 4 hours post-dose; CI,
confidence interval; EOS, eosinophil; FEV<sub>1</sub>, forced expiratory
volume in 1 second; GFF, glycopyrrolate/formoterol fumarate; ICS,
inhaled corticosteroid.</p>
                  </caption>
                  <graphic xlink:href="10.1177_17534666211034329-fig4" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="section18-17534666211034329">
              <title>Discussion</title>
              <p>The findings of this 4-hour PFT sub-study of ETHOS demonstrated the benefit of BGF
<italic toggle="yes">versus</italic> GFF and BFF on both morning pre-dose trough
FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–4</sub> for the first 24 weeks of
treatment. These improvements in lung function were sustained at week 52. These
findings are in line with the recommendations in the GOLD report, which notes that
triple therapy can improve lung function <italic toggle="yes">versus</italic> dual LAMA/LABA and
ICS/LABA therapies.<sup><xref rid="bibr3-17534666211034329" ref-type="bibr">3</xref></sup> While ETHOS was the first study of a triple fixed-dose combination therapy to
evaluate two different ICS doses in the same study, it was not designed or powered
to detect significant differences between the doses of BGF. Numerical trends in
favor of BGF 320/18/9.6 μg over BGF 160/18/9.6 μg relative to GFF were observed for
the PFT sub-study primary endpoints; however, these differences were not large. The
effects of the ICS component of BGF, as reflected by improvements in trough
FEV<sub>1</sub> with BGF <italic toggle="yes">versus</italic> GFF, were greatest in the
subgroup of patients with FEV<sub>1</sub> ⩾ 50% predicted and eosinophil counts
⩾100 cells/mm<sup>3</sup>.</p>
              <p>The benefits of BGF 320/18/9.6 μg on lung function at week 24 observed in ETHOS are
consistent with data from the KRONOS study, in which BGF demonstrated significant
improvements in lung function relative to ICS/LABA dual therapy.<sup><xref rid="bibr9-17534666211034329" ref-type="bibr">9</xref></sup> As in ETHOS, a statistically significant improvement in FEV<sub>1</sub>
AUC<sub>0–4</sub> at week 24 was also observed for BGF 320/18/9.6 μg compared
with BFF in KRONOS. However, unlike ETHOS, the improvement in change from baseline
in morning pre-dose trough FEV<sub>1</sub> at week 24 compared with GFF in KRONOS
was numerical, but did not achieve statistical significance.<sup><xref rid="bibr9-17534666211034329" ref-type="bibr">9</xref></sup> Nonetheless, it is important to note that analyses at week 24 with the
attributable estimand in KRONOS, which factored in missing data, did demonstrate a
significant difference between BGF 320/18/9.6 μg and GFF for trough FEV<sub>1</sub>
(24 mL; unadjusted <italic toggle="yes">p</italic>-value = 0.0370). This suggested that missing
data played an important role in the trough FEV<sub>1</sub> results for BGF
320/18/9.6 μg <italic toggle="yes">versus</italic> GFF in KRONOS.</p>
              <p>As reported previously, lung function improvements with an ICS are known to be
associated with blood eosinophil counts.<sup><xref rid="bibr15-17534666211034329" ref-type="bibr">15</xref><xref rid="bibr16-17534666211034329" ref-type="bibr"/><xref rid="bibr17-17534666211034329" ref-type="bibr"/><xref rid="bibr18-17534666211034329" ref-type="bibr"/><xref rid="bibr19-17534666211034329" ref-type="bibr"/>–<xref rid="bibr20-17534666211034329" ref-type="bibr">20</xref></sup> In this regard, the
percentage of patients with baseline blood eosinophil levels
&lt;150 cells/mm<sup>3</sup> was 48.2% and 40.0% in the overall populations for
KRONOS and ETHOS, respectively. The percentage of patients with blood eosinophil
levels &lt;150 cells/mm<sup>3</sup> was considerably higher in KRONOS compared with
ETHOS, which may explain the lower magnitude of benefit observed in pre-dose trough
FEV<sub>1</sub> for BGF relative to GFF at week 24 in KRONOS. Nonetheless, the
improvements observed in morning pre-dose trough FEV<sub>1</sub> at week 24 in ETHOS
for BGF relative to GFF (35 mL) were consistent with values observed for the ICS
component for this endpoint in other triple fixed-dose combinations at week 24 or
week 26 (20 mL to 81 mL).<sup><xref rid="bibr15-17534666211034329" ref-type="bibr">15</xref>,<xref rid="bibr18-17534666211034329" ref-type="bibr">18</xref>,<xref rid="bibr21-17534666211034329" ref-type="bibr">21</xref></sup></p>
              <p>Although the current study was not designed to evaluate lung function decline, a
trend for a lower rate of decline in morning pre-dose trough FEV<sub>1</sub> over
52 weeks was observed for both doses of BGF relative to GFF. No consistent effects
were observed for rate of decline in FEV<sub>1</sub> AUC<sub>0–4</sub> over 52 weeks
for BGF relative to BFF. However, exploratory analyses pooling ICS-containing
therapies were also conducted to evaluate the effects of blood eosinophils and lung
function severity on lung function decline, as these factors are known to modulate
the lung function benefits of ICS in COPD. Results using the pooled data suggested
that greater reductions in the annual rate of lung function decline relative to the
LAMA/LABA occurred in patients with moderate airflow obstruction and those with a
baseline blood eosinophil count ⩾100 cells/mm<sup>3</sup>. Although speculative,
these findings suggest that there may be value in initiating ICS therapy to prevent
lung function decline in COPD patients with eosinophil counts
⩾100 cells/mm<sup>3</sup> and less severe lung function impairment, rather than
waiting until a marked loss of lung function has already occurred. Clearly,
prospective studies aimed at reducing the rate of lung function decline earlier in
the COPD disease process are needed.</p>
              <p>In conclusion, both BGF 320/18/9.6 μg and BGF 160/18/9.6 μg provided significant
improvements in lung function at week 24 <italic toggle="yes">versus</italic> GFF and BFF in
patients with moderate to very severe COPD. The benefits on lung function were
sustained <italic toggle="yes">versus</italic> ICS/LABA and LAMA/LABA dual therapies over
52 weeks. The lung function improvements observed in this sub-study complement the
improvements observed in exacerbations, symptoms, and quality of life in the overall
ETHOS study in patients with moderate to very severe COPD.</p>
            </sec>
            <sec sec-type="supplementary-material" id="section19-17534666211034329" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material id="suppl1-17534666211034329" position="float" content-type="local-data">
                <caption>
                  <title>sj-pdf-1-tar-10.1177_17534666211034329 – Supplemental material for
Improvements in lung function with budesonide/glycopyrrolate/formoterol
fumarate metered dose inhaler versus dual therapies in patients with COPD: a
sub-study of the ETHOS trial</title>
                </caption>
                <media xlink:href="sj-pdf-1-tar-10.1177_17534666211034329.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-pdf-1-tar-10.1177_17534666211034329 for Improvements in
lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS
trial by Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin
Jenkins, Patrick Darken, Magnus Aurivillius and Paul Dorinsky in Therapeutic
Advances in Respiratory Disease</p>
              </supplementary-material>
              <supplementary-material id="suppl2-17534666211034329" position="float" content-type="local-data">
                <caption>
                  <title>sj-pdf-2-tar-10.1177_17534666211034329 – Supplemental material for
Improvements in lung function with budesonide/glycopyrrolate/formoterol
fumarate metered dose inhaler versus dual therapies in patients with COPD: a
sub-study of the ETHOS trial</title>
                </caption>
                <media xlink:href="sj-pdf-2-tar-10.1177_17534666211034329.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-pdf-2-tar-10.1177_17534666211034329 for Improvements in
lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS
trial by Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin
Jenkins, Patrick Darken, Magnus Aurivillius and Paul Dorinsky in Therapeutic
Advances in Respiratory Disease</p>
              </supplementary-material>
              <supplementary-material id="suppl3-17534666211034329" position="float" content-type="local-data">
                <caption>
                  <title>sj-pdf-3-tar-10.1177_17534666211034329 – Supplemental material for
Improvements in lung function with budesonide/glycopyrrolate/formoterol
fumarate metered dose inhaler versus dual therapies in patients with COPD: a
sub-study of the ETHOS trial</title>
                </caption>
                <media xlink:href="sj-pdf-3-tar-10.1177_17534666211034329.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-pdf-3-tar-10.1177_17534666211034329 for Improvements in
lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS
trial by Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin
Jenkins, Patrick Darken, Magnus Aurivillius and Paul Dorinsky in Therapeutic
Advances in Respiratory Disease</p>
              </supplementary-material>
              <supplementary-material id="suppl4-17534666211034329" position="float" content-type="local-data">
                <caption>
                  <title>sj-pdf-4-tar-10.1177_17534666211034329 – Supplemental material for
Improvements in lung function with budesonide/glycopyrrolate/formoterol
fumarate metered dose inhaler versus dual therapies in patients with COPD: a
sub-study of the ETHOS trial</title>
                </caption>
                <media xlink:href="sj-pdf-4-tar-10.1177_17534666211034329.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-pdf-4-tar-10.1177_17534666211034329 for Improvements in
lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS
trial by Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin
Jenkins, Patrick Darken, Magnus Aurivillius and Paul Dorinsky in Therapeutic
Advances in Respiratory Disease</p>
              </supplementary-material>
              <supplementary-material id="suppl5-17534666211034329" position="float" content-type="local-data">
                <caption>
                  <title>sj-pdf-5-tar-10.1177_17534666211034329 – Supplemental material for
Improvements in lung function with budesonide/glycopyrrolate/formoterol
fumarate metered dose inhaler versus dual therapies in patients with COPD: a
sub-study of the ETHOS trial</title>
                </caption>
                <media xlink:href="sj-pdf-5-tar-10.1177_17534666211034329.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-pdf-5-tar-10.1177_17534666211034329 for Improvements in
lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS
trial by Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin
Jenkins, Patrick Darken, Magnus Aurivillius and Paul Dorinsky in Therapeutic
Advances in Respiratory Disease</p>
              </supplementary-material>
              <supplementary-material id="suppl6-17534666211034329" position="float" content-type="local-data">
                <caption>
                  <title>sj-pdf-6-tar-10.1177_17534666211034329 – Supplemental material for
Improvements in lung function with budesonide/glycopyrrolate/formoterol
fumarate metered dose inhaler versus dual therapies in patients with COPD: a
sub-study of the ETHOS trial</title>
                </caption>
                <media xlink:href="sj-pdf-6-tar-10.1177_17534666211034329.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-pdf-6-tar-10.1177_17534666211034329 for Improvements in
lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS
trial by Klaus F. Rabe, Fernando J. Martinez, Dave Singh, Roopa Trivedi, Martin
Jenkins, Patrick Darken, Magnus Aurivillius and Paul Dorinsky in Therapeutic
Advances in Respiratory Disease</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors would like to thank all the patients, their families, and the
investigators, research nurses, and operations staff involved in ETHOS. The authors
also thank Julie McLaren, Earl St Rose, Shaila Ballal, and Colin Reisner, who were
employees of AstraZeneca when this study was conducted, and held stock options in
the company, for their valuable contribution to the study. Medical writing support,
under the direction of the authors, was provided by Jake Casson, CMC Connect, McCann
Health Medical Communications, and was funded by AstraZeneca in accordance with Good
Publication Practice (GPP3) guidelines.<sup><xref rid="bibr22-17534666211034329" ref-type="bibr">22</xref></sup></p>
              <p>Dave Singh is supported by the National Institute for Health Research (NIHR)
Manchester Biomedical Research Centre (BRC)</p>
            </ack>
            <fn-group>
              <fn fn-type="con">
                <p><bold>Author contributions:</bold> The authors meet the criteria for authorship as recommended by the International
Committee of Medical Journal Editors, take responsibility for the integrity of
the work as a whole, contributed to the writing and reviewing of the manuscript,
and have given final approval for the version to be published. All authors had
full access to the data in this study and take complete responsibility for the
integrity of the data and accuracy of the data analysis.</p>
                <p>Klaus F Rabe, Fernando J Martinez, Dave Singh, Roopa Trivedi, and Magnus
Aurivillius: Acquisition of data; data interpretation.</p>
                <p>Martin Jenkins, Patrick Darken, and Paul Dorinsky: Conception/design; data
analysis/interpretation.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Conflict of interest statement:</bold> Klaus F Rabe reports personal fees from AstraZeneca, Berlin-Chemie, Boehringer
Ingelheim, Chiesi Pharmaceuticals, InterMune, Novartis, Sanofi, and Teva; and
grants from the Ministry of Education and Science, Germany, outside the
submitted work.</p>
                <p>Fernando J Martinez reports grants from AstraZeneca during the conduct of the
study; personal fees and non-financial support from the American College of
Chest Physicians, AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals,
Concert, Continuing Education, Genentech, GlaxoSmithKline, Inova Fairfax Health
System, Miller Communications, the National Association for Continuing
Education, Novartis, PeerView Communications, Prime Communications, the Puerto
Rican Respiratory Society, Roche, Sunovion, and Theravance; non-financial
support from ProterixBio; and personal fees from the American Thoracic Society,
Columbia University, Haymarket Communications, Integritas, inThought Research,
MD Magazine, Methodist Hospital Brooklyn, New York University, Unity,
Up-To-Date, WebMD/MedScape, and Western Connecticut Health Network; and grants
from the National Institutes of Health, outside the submitted work.</p>
                <p>Dave Singh reports personal fees from Apellis, Cipla, Genentech, Peptinnovate,
and Skyepharma; and grants and personal fees from AstraZeneca, Boehringer
Ingelheim, Chiesi Pharmaceuticals, GlaxoSmithKline, Glenmark, Menarini, Merck,
Mundipharma, Novartis, Pfizer, Pulmatrix, Teva, Theravance, and Verona, outside
the submitted work.</p>
                <p>Roopa Trivedi, Martin Jenkins, Patrick Darken, Magnus Aurivillius, and Paul
Dorinsky are employees of AstraZeneca and hold stock and/or stock options in the
company.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This study was
supported by AstraZeneca. The funder of the study had a role in study design,
data collection, data analysis, data interpretation, and writing of the report.
All authors had full access to all of the data in this study and take complete
responsibility for the integrity of the data and the accuracy of the data
analysis.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Data availability:</bold> Data underlying the findings described in this manuscript may be obtained in
accordance with AstraZeneca’s data sharing policy described at <ext-link xlink:href="https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure" ext-link-type="uri">https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ext-link>.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iD:</bold> Klaus F Rabe <inline-graphic xlink:href="10.1177_17534666211034329-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0002-7020-1401" ext-link-type="uri">https://orcid.org/0000-0002-7020-1401</ext-link></p>
              </fn>
              <fn fn-type="supplementary-material">
                <p><bold>Supplemental material:</bold> The reviews of this paper are available via the supplemental material
section.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-17534666211034329">
                <label>1</label>
                <mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <source>Global health estimates
2016: deaths by cause, age, sex, by country and by region
2000–2016</source>. <ext-link xlink:href="https://www.who.int/healthinfo/global_burden_disease/estimates/en/" ext-link-type="uri">https://www.who.int/healthinfo/global_burden_disease/estimates/en/</ext-link>
(<year>2018</year>; <comment>accessed 11 April
2019</comment>).</mixed-citation>
              </ref>
              <ref id="bibr2-17534666211034329">
                <label>2</label>
                <mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. <source>Global health estimates:
life expectancy and leading causes of death and disability</source>.
<ext-link xlink:href="https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates" ext-link-type="uri">https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates</ext-link>
(<year>2020</year>; <comment>accessed January 6
2020</comment>).</mixed-citation>
              </ref>
              <ref id="bibr3-17534666211034329">
                <label>3</label>
                <mixed-citation publication-type="webpage"><collab>Global Initiative for Chronic Obstructive Lung Disease</collab>.
<source>Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease</source>. <ext-link xlink:href="https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-16Nov20_WMV.pdf" ext-link-type="uri">https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-16Nov20_WMV.pdf</ext-link>
(<year>2021</year>; <comment>accessed 18 November
2020</comment>).</mixed-citation>
              </ref>
              <ref id="bibr4-17534666211034329">
                <label>4</label>
                <mixed-citation publication-type="journal"><collab>GBD 2017 Disease and Injury Incidence and Prevalence
Collaborators</collab>. <article-title>Global, regional, and national
incidence, prevalence, and years lived with disability for 354 diseases and
injuries for 195 countries and territories, 1990–2017: a systematic analysis
for the Global Burden of Disease Study 2017</article-title>.
<source>Lancet</source><year>2018</year>; <volume>392</volume>:
<fpage>1789</fpage>–<lpage>1858</lpage>.<pub-id pub-id-type="pmid">30496104</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-17534666211034329">
                <label>5</label>
                <mixed-citation publication-type="journal"><collab>GBD 2017 Causes of Death Collaborators</collab>. <article-title>Global,
regional, and national age-sex-specific mortality for 282 causes of death in
195 countries and territories, 1980–2017: a systematic analysis for the
Global Burden of Disease Study 2017</article-title>. <source>Lancet</source><year>2018</year>; <volume>392</volume>:
<fpage>1736</fpage>–<lpage>1788</lpage>.<pub-id pub-id-type="pmid">30496103</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-17534666211034329">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burge</surname><given-names>S</given-names></name><name><surname>Wedzicha</surname><given-names>JA.</given-names></name></person-group><article-title>COPD exacerbations: definitions and
classifications</article-title>. <source>Eur Respir J</source><year>2003</year>; <volume>21</volume>:
<fpage>46s</fpage>–<lpage>53s</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr7-17534666211034329">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name></person-group>, <etal>et al</etal>. <article-title>Triple inhaled therapy at
two glucocorticoid doses in moderate-to-very-severe COPD</article-title>.
<source>N Engl J Med</source><year>2020</year>; <volume>383</volume>:
<fpage>35</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">32579807</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-17534666211034329">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name></person-group>, <etal>et al</etal>. <article-title>Reduced all-cause mortality
in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a
randomized, double-blind, multi-center parallel-group study</article-title>.
<source>Am J Respir Crit Care Med</source><year>2021</year>; <volume>203</volume>:
<fpage>553</fpage>–<lpage>564</lpage>.<pub-id pub-id-type="pmid">33252985</pub-id></mixed-citation>
              </ref>
              <ref id="bibr9-17534666211034329">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Triple therapy with
budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery
technology versus dual therapies in chronic obstructive pulmonary disease
(KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised
controlled trial</article-title>. <source>Lancet Respir Med</source><year>2018</year>; <volume>6</volume>:
<fpage>747</fpage>–<lpage>758</lpage>.<pub-id pub-id-type="pmid">30232048</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-17534666211034329">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>Seasonal variation in COPD
exacerbations: a post-hoc analysis from the KRONOS phase III study of
budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF
MDI)</article-title>. <source>Am J Respir Crit Care Med</source><year>2020</year>; <volume>199</volume>: <fpage>A1571</fpage>.</mixed-citation>
              </ref>
              <ref id="bibr11-17534666211034329">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name></person-group>, <etal>et al</etal>. <article-title>A phase III study of triple
therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery
technology in moderate-to-very severe COPD: the ETHOS study
protocol</article-title>. <source>Respir Med</source><year>2019</year>; <volume>158</volume>:
<fpage>59</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">31605923</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-17534666211034329">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal>. <article-title>Standardisation of
spirometry</article-title>. <source>Eur Respir J</source><year>2005</year>; <volume>26</volume>:
<fpage>319</fpage>–<lpage>338</lpage>.<pub-id pub-id-type="pmid">16055882</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-17534666211034329">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Brook</surname><given-names>RD</given-names></name></person-group>, <etal>et al</etal>. <article-title>Fluticasone furoate and
vilanterol and survival in chronic obstructive pulmonary disease with
heightened cardiovascular risk (SUMMIT): a double-blind randomised
controlled trial</article-title>. <source>Lancet</source><year>2016</year>; <volume>387</volume>:
<fpage>1817</fpage>–<lpage>1826</lpage>.<pub-id pub-id-type="pmid">27203508</pub-id></mixed-citation>
              </ref>
              <ref id="bibr14-17534666211034329">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>Thomas</surname><given-names>NE</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of pharmacotherapy on
rate of decline of lung function in chronic obstructive pulmonary disease:
results from the TORCH study</article-title>. <source>Am J Respir Crit Care
Med</source><year>2008</year>; <volume>178</volume>:
<fpage>332</fpage>–<lpage>338</lpage>.<pub-id pub-id-type="pmid">18511702</pub-id></mixed-citation>
              </ref>
              <ref id="bibr15-17534666211034329">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipson</surname><given-names>DA</given-names></name><name><surname>Barnhart</surname><given-names>F</given-names></name><name><surname>Brealey</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>. <article-title>Once-daily single-inhaler
triple versus dual therapy in patients with COPD</article-title>. <source>N
Engl J Med</source><year>2018</year>; <volume>378</volume>:
<fpage>1671</fpage>–<lpage>1680</lpage>.<pub-id pub-id-type="pmid">29668352</pub-id></mixed-citation>
              </ref>
              <ref id="bibr16-17534666211034329">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bafadhel</surname><given-names>M</given-names></name><name><surname>Peterson</surname><given-names>S</given-names></name><name><surname>De Blas</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Predictors of exacerbation
risk and response to budesonide in patients with chronic obstructive
pulmonary disease: a post-hoc analysis of three randomised
trials</article-title>. <source>Lancet Respir Med</source><year>2018</year>; <volume>6</volume>:
<fpage>117</fpage>–<lpage>126</lpage>.<pub-id pub-id-type="pmid">29331313</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-17534666211034329">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>SH</given-names></name><name><surname>Guasconi</surname><given-names>A</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Blood eosinophils: a
biomarker of response to extrafine beclomethasone/formoterol in chronic
obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care
Med</source><year>2015</year>; <volume>192</volume>:
<fpage>523</fpage>–<lpage>525</lpage>.<pub-id pub-id-type="pmid">26051430</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-17534666211034329">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papi</surname><given-names>A</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Fabbri</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>Extrafine inhaled triple
therapy versus dual bronchodilator therapy in chronic obstructive pulmonary
disease (TRIBUTE): a double-blind, parallel group, randomised controlled
trial</article-title>. <source>Lancet</source><year>2018</year>; <volume>391</volume>:
<fpage>1076</fpage>–<lpage>1084</lpage>.<pub-id pub-id-type="pmid">29429593</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-17534666211034329">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascoe</surname><given-names>S</given-names></name><name><surname>Locantore</surname><given-names>N</given-names></name><name><surname>Dransfield</surname><given-names>MT</given-names></name></person-group>, <etal>et al</etal>. <article-title>Blood eosinophil counts,
exacerbations, and response to the addition of inhaled fluticasone furoate
to vilanterol in patients with chronic obstructive pulmonary disease: a
secondary analysis of data from two parallel randomised controlled
trials</article-title>. <source>Lancet Respir Med</source><year>2015</year>; <volume>3</volume>:
<fpage>435</fpage>–<lpage>442</lpage>.<pub-id pub-id-type="pmid">25878028</pub-id></mixed-citation>
              </ref>
              <ref id="bibr20-17534666211034329">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Roisin</surname><given-names>R</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Global initiative for
Chronic Obstructive Lung Disease (GOLD) 20th anniversary: a brief history of
time</article-title>. <source>Eur Respir J</source><year>2017</year>; <volume>50</volume>: <fpage>1700671</fpage>.<pub-id pub-id-type="pmid">28679615</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-17534666211034329">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Papi</surname><given-names>A</given-names></name><name><surname>Corradi</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Single inhaler triple
therapy versus inhaled corticosteroid plus long-acting β<sub>2</sub>-agonist
therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind,
parallel group, randomised controlled trial</article-title>.
<source>Lancet</source><year>2016</year>; <volume>388</volume>:
<fpage>963</fpage>–<lpage>973</lpage>.<pub-id pub-id-type="pmid">27598678</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-17534666211034329">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battisti</surname><given-names>WP</given-names></name><name><surname>Wager</surname><given-names>E</given-names></name><name><surname>Baltzer</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>Good publication practice
for communicating company-sponsored medical research: GPP3</article-title>.
<source>Ann Intern Med</source><year>2015</year>; <volume>163</volume>:
<fpage>461</fpage>–<lpage>464</lpage>.<pub-id pub-id-type="pmid">26259067</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
